# Modern experimental methods for assessing the effectiveness of tissue-engineered products for hyaline cartilage regeneration

**Authors:** M. S. Bozhokin, Yu. S. Korneva, S. A. Bozhkova, E. R. Mikhaylova, D. M. Marchenko, B. R. Rakhimov, Y. A. Nashchekina, M. G. Khotin

PMC · DOI: 10.3389/fbioe.2025.1595116 · Frontiers in Bioengineering and Biotechnology · 2025-07-21

## TL;DR

This paper reviews modern methods for evaluating tissue-engineered products aimed at regenerating hyaline cartilage, a tissue with limited self-repair ability.

## Contribution

The study systematically evaluates the effectiveness of various analytical methods for tissue-engineered hyaline cartilage constructs.

## Key findings

- A range of methods is needed to assess scaffold structure and mechanical properties in tissue-engineered hyaline cartilage.
- Cell behavior within the scaffold is critical to evaluate at all stages of development and post-transplantation.
- Optimization of analytical methods is necessary due to scaffold opacity and architectural complexity.

## Abstract

Hyaline cartilage (HC) is a specialized connective tissue that covers the surfaces of major joints and is characterized by its limited regenerative capacity. Modern therapeutic approaches to HC restoration often do not provide complete regeneration of damaged tissue. Developed tissue engineering methods show promise as effective approaches for restoring various types of HC damage. Due to the rapid evolution of various technologies in research practice, the range of methods available for analysis of TE constructs has expanded, including for the study of tissue engineering of hyaline cartilage (TEHC). Because of the complexity of the HC’s structure, a whole range of methods is needed to assess characteristics of the scaffold, such as structure and strength. It is also important to study the behavior of cells inside the TE construct at all stages of cultivation, including post transplantation into the damaged area. The opacity of the scaffold and the complexity of its architecture often cause issues with the cell visualization and assessment of their viability. Therefore, there is a need to optimize each specific method for each specific scaffold. Despite the active study of TEHC, the results remain unsatisfactory. In this study, we have systematized data on the effectiveness and feasibility of methods to analyze structure, mechanical characteristics, cell interaction with the scaffold, and their ability to form new tissue before and after transplantation.

## Full-text entities

- **Genes:** SLC16A1 (solute carrier family 16 member 1) [NCBI Gene 6566] {aka HHF7, MCT, MCT1, MCT1D}, THY1 (Thy-1 cell surface antigen) [NCBI Gene 7070] {aka CD90, CDw90}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Col2a1 (collagen type II alpha 1 chain) [NCBI Gene 25412] {aka CG2A1A, COLLII}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, CD34 (CD34 molecule) [NCBI Gene 947], IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, NT5E (5'-nucleotidase ecto) [NCBI Gene 4907] {aka CALJA, CD73, E5NT, NT, NT5, NTE}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, ITGB1 (integrin subunit beta 1) [NCBI Gene 3688] {aka CD29, FNRB, GPIIA, MDF2, MSK12, VLA-BETA}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, BMP7 (bone morphogenetic protein 7) [NCBI Gene 655] {aka OP-1}, Col1a1 (collagen type I alpha 1 chain) [NCBI Gene 29393] {aka COLIA1}, DECR1 (2,4-dienoyl-CoA reductase 1) [NCBI Gene 1666] {aka DECR, NADPH, SDR18C1}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, SOX6 (SRY-box transcription factor 6) [NCBI Gene 55553] {aka HSSOX6, SOXD, TOLCAS}, COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278] {aka EDSARTH2, EDSCV, OI4}, GDF5 (growth differentiation factor 5) [NCBI Gene 8200] {aka BDA1C, BMP-14, BMP14, CDMP1, DUPANS, LAP-4}, ALCAM (activated leukocyte cell adhesion molecule) [NCBI Gene 214] {aka CD166, MEMD}, CD14 (CD14 molecule) [NCBI Gene 929], SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662] {aka CMD1, CMPD1, ENH13, SRA1, SRXX2, SRXY10}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, Acan (aggrecan) [NCBI Gene 58968] {aka Agc, Agc1}, CNMD (chondromodulin) [NCBI Gene 11061] {aka BRICD3, CHM-I, CHM1, LECT1, MYETS1}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, MIA3 (MIA SH3 domain ER export factor 3) [NCBI Gene 375056] {aka D320, ODCD2, TANGO, TANGO1, UNQ6077}, TGFB3 (transforming growth factor beta 3) [NCBI Gene 7043] {aka ARVD, ARVD1, LDS5, RNHF, TGF-beta3}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, Col10a1 (collagen type X alpha 1 chain) [NCBI Gene 25681], ACAN (aggrecan) [NCBI Gene 176] {aka AGC1, AGCAN, CSPG1, CSPGCP, MSK16, SEDK}, COL2A1 (collagen type II alpha 1 chain) [NCBI Gene 1280] {aka ACG2, ANFH, ANFH1, AOM, COL11A3, EDMMD}
- **Diseases:** trauma (MESH:D014947), cytotoxic (MESH:D064420), osteochondral defect (MESH:D010007), OCD (MESH:D009771), calcification (MESH:D002114), osteochondritis dissecans (MESH:D010008), cartilage hypertrophy (MESH:D006984), DM (MESH:D009223), Hyaline cartilage (MESH:D002357), juvenile idiopathic arthritis (MESH:D001171), OA (MESH:D010003)
- **Chemicals:** GAG (MESH:D006025), IPFP (-), amines (MESH:D000588), MTT (MESH:C070243), Calcein AM (MESH:C085925), CS (MESH:D002586), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MESH:C022616), paraffin (MESH:D010232), hematoxylin (MESH:D006416), Calcein (MESH:C007740), Alcian blue (MESH:D000423), CCK 8 (MESH:D012844), sGAG (MESH:C013786), tricalcium phosphate (MESH:C018392), PI (MESH:D010716), DAPI (MESH:C007293), hydroxyapatite (MESH:D017886), Hexabrix (MESH:D007485), chitosan (MESH:D048271), polyacrylamide (MESH:C016679), Safranin O (MESH:C009195), ascorbic acid (MESH:D001205), Alizarin red (MESH:C010078), polycaprolactone (MESH:C016240), Fast Green (MESH:C035906), formazan (MESH:D005562), propidium iodide (MESH:D011419), H (MESH:D006859), Polymer (MESH:D011108), chondroitin sulfate (MESH:D002809), ethidium homodimer-1 (MESH:C018533), tetrazolium (MESH:D013778), hyaluronic acid (MESH:D006820), CEC (MESH:C051731), eosin (MESH:D004801), iothalamate (MESH:D007483), H&amp;E (MESH:D006371)
- **Species:** Sus scrofa (pig, species) [taxon 9823], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Homo sapiens (human, species) [taxon 9606], Actinopterygii (fishes, superclass) [taxon 7898], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** L929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58), hASC — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_A9ZM), TEHC — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_6E91), OC — Homo sapiens (Human), Ovarian serous cystadenocarcinoma, Cancer cell line (CVCL_A1GZ)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12318997/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12318997/full.md

## References

117 references — full list in the complete paper: https://tomesphere.com/paper/PMC12318997/full.md

---
Source: https://tomesphere.com/paper/PMC12318997